GSA to cut 577 schedule vendors, 31 SINs

[ad_1] The General Services Administration is targeting as many as 577 schedule holders for removal in the next six months. These are companies who have either not met their sales quota in the last year or have performance or compliance issues. Additionally, GSA is planning on removing 31 Special Item Numbers (SINs) under the schedules […]

Ten years later, agencies still making gains on category management

[ad_1] What: Federal agencies move to best-in-class contracting and category management When: “Transforming the Marketplace” memo published by the Office of Federal Procurement Policy in December 2014 Why it matters: OFPP’s push toward category management turned out not to be just an acquisition policy fad, but one that continues to influence agency procurement decisions to […]

Optimizing the multiple award schedule program

[ad_1] Optimizing the multiple award schedule program The MAS program contracts are awarded at fair and reasonable prices and promote the best pricing through competition at the task. Roger Waldron March 28, 2025 12:12 pm 3 min read On Monday, the General Services Administration (GSA) announced major changes to the Multiple Award Schedule (MAS) program. […]

Purchase card freeze paralyzes small business, leaves agencies scrambling

[ad_1] A freeze on government credit cards is leaving small businesses with paused orders, unpaid invoices and no way to process new purchases since the federal agencies don’t have the means to pay for them. The Department of Government Efficiency, led by billionaire and White House advisor Elon Musk, started cracking down on routine federal […]

Trump administration contracting freeze puts vendors out of business

[ad_1] Trump administration contracting freeze puts vendors out of business In today’s Federal Newscast, the Trump administration’s contracting freeze has caused several contractors to go out of business. Eric White@FEDERALNEWSCAST March 28, 2025 12:56 pm < a min read The Trump administration’s contracting freeze has caused several contractors to go out of business. The Professional […]

DLA Awards Combined $150M MRO Contract to Supplycore, ASRC Federal

[ad_1] “Seal of the Defense Logistics Agency,” by the Defense Logistics Agency, Licensed under Public Domain Supplycore and ASRC Federal have received contracts with a combined maximum value of $150 million from the Defense Logistics Agency for maintenance, repair and operations, or MRO, support services. DLA’s MRO Contract Details The Department of Defense said each company was awarded a […]

Pfizer’s $60M Reality Check: A Chaotic but Crucial Lesson in Compliance

Pfizer false claims settlement compliance blog post illustration

In January 2025, pharmaceutical giant Pfizer made headlines when it agreed to pay nearly $60 million to resolve allegations involving its acquisition, Biohaven Pharmaceutical Holding Company Ltd. The U.S. Department of Justice alleged that Biohaven caused the submission of false claims to federal healthcare programs—including Medicare—by offering kickbacks to providers in exchange for prescribing its migraine treatment, Nurtec ODT. While Pfizer did not admit wrongdoing, the case […]

How Public-Private Partnerships Are Reshaping Federal Projects Under Trump

Public-Private Partnerships Reshaping Federal Infrastructure Projects

The Rise (and Chaos) of Public-Private Partnerships in Trump’s Infrastructure Plan Public-Private Partnerships (PPPs). The future of infrastructure? Or a bureaucratic maze designed to confuse even the most seasoned federal contractor? Well, under Trump, this funding model wasn’t just encouraged—it became the backbone of America’s infrastructure strategy. Whether that’s a genius move or a logistical […]

Pfizer’s 2025 Financial Outlook: A Corporate Powerhouse or a Market Mirage?

Pfizer’s financial outlook amid government contract shifts

The Tightrope Between Profit and Public Good Pfizer has long been a major player in the pharmaceutical industry, leveraging both innovation and strategic partnerships to maintain its market position. Pfizer is a behemoth. No question about it. The pharmaceutical titan, famous (or infamous, depending on who you ask) for its COVID-19 treatments just dropped its 2025 […]